GENETIC PRECISION, PERSONALIZED MEDICINE Trademark

Trademark Overview

On Wednesday, June 28, 2017, a trademark application was filed for GENETIC PRECISION, PERSONALIZED MEDICINE with the United States Patent and Trademark Office. The USPTO has given the GENETIC PRECISION, PERSONALIZED MEDICINE trademark a serial number of 87509291. The federal status of this trademark filing is SECTION 8 - ACCEPTED as of Tuesday, April 22, 2025. This trademark is owned by NucleoBio, Inc.. The GENETIC PRECISION, PERSONALIZED MEDICINE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical research; Medical research services in the field of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Pharmaceutical drug development services
genetic precision, personalized medicine

General Information

Serial Number87509291
Word MarkGENETIC PRECISION, PERSONALIZED MEDICINE
Filing DateWednesday, June 28, 2017
Status701 - SECTION 8 - ACCEPTED
Status DateTuesday, April 22, 2025
Registration Number5596723
Registration DateTuesday, October 30, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 23, 2018

Trademark Statements

NOT AVAILABLE"PERSONALIZED MEDICINE"
Goods and ServicesMedical research; Medical research services in the field of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Pharmaceutical drug development services

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, July 6, 2017
Primary Code042
First Use Anywhere DateFriday, March 31, 2017
First Use In Commerce DateTuesday, November 14, 2017

Trademark Owner History

Party NameNucleoBio, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Antonio, TX 78253
Party NameNucleoBio, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Antonio, TX 78253
Party NameNucleoBio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Antonio, TX 78253

Trademark Events

Event DateEvent Description
Friday, September 15, 2017ASSIGNED TO EXAMINER
Monday, September 18, 2017NON-FINAL ACTION WRITTEN
Saturday, July 1, 2017NEW APPLICATION ENTERED
Thursday, July 6, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, November 29, 2017ASSIGNED TO LIE
Tuesday, January 23, 2018PUBLISHED FOR OPPOSITION
Monday, September 18, 2017NON-FINAL ACTION E-MAILED
Monday, September 18, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, November 15, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, November 30, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 30, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 12, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 3, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, August 22, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, August 23, 2018STATEMENT OF USE PROCESSING COMPLETE
Monday, October 30, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, January 23, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 20, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, July 25, 2018TEAS STATEMENT OF USE RECEIVED
Wednesday, July 25, 2018USE AMENDMENT FILED
Monday, September 24, 2018ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, September 25, 2018NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, October 30, 2018REGISTERED-PRINCIPAL REGISTER
Tuesday, April 22, 2025CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, April 22, 2025REGISTERED - SEC. 8 (6-YR) ACCEPTED
Tuesday, April 22, 2025NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Tuesday, October 29, 2024TEAS SECTION 8 RECEIVED

Related Keywords

medicine personalized precision genetic medical research cancer field services drug development pharmaceutical scientific treatment